adara development (usa)

NYS Entity Status
ACTIVE

NYS Filing Date
OCTOBER 08, 2014

NYS DOS ID#
4648276

County

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC NOT-FOR-PROFIT CORPORATION RESERVATION

Name History
2014 - ADARA DEVELOPMENT (USA)









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • New Development: Soft in the Middle, Splashy Up Top
    By STEFANOS CHEN - Friday Sep 15, 2017

    The luxury market in New York is pulling in two directions, with developers betting on big-ticket palatial aeries and million-dollar “starter” homes.

    Source: NYT > Home Page
  • A Dip in the Living Room Pool
    Friday Sep 15, 2017

    In a slowing luxury real estate market, developers are investing in amenities to attract buyers. Explore Soori High Line, where more than half of the units come with private, saltwater pools.

    Source: NYT > Home Page
  • Bill and Hillary Clinton's Hamptons Summer Rental Sells
    Tuesday Aug 29, 2017

    In East Hampton, N.Y., the property was sold by real estate developer Elie Hirschfeld, president of Hirschfeld Properties.

    Source: The Wall Street Journal: Lifestyle
  • Owner Hopes to Remake Resort That Inspired ‘Dirty Dancing’
    By SARAH MASLIN NIR - Wednesday Aug 9, 2017

    Grossinger’s was once the most glamorous of the summer vacation spots that dotted the Catskills. A developer envisions its revival.

    Source: NYT > Home Page
  • 360 View: The Headache of Living Next to Endless Construction
    By RONDA KAYSEN - Friday Sep 15, 2017

    Construction scaffolding is a part of New York City’s streetscape. When it happens next door, developers sometimes pay neighbors for their trouble.

    Source: NYT > Home Page
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York